Navrogen Publishes Breakthrough on NAV-005, A CA125 Antagonist That Improves Antibody Cancer Therapy and ADC Efficacy

The research highlights how NAV-005 overcomes the immunosuppressive effects that tumor-produced CA125 has on antibodies ...

VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its ...

Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight

Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with ...
Le Lézard

Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight

Recently published Nephrotic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, nephrotic syndrome emerging drugs, market share of individual ...

Warm Autoimmune Hemolytic Anemia Market to Observe Stunning Growth at a 14.4% CAGR During the Forecast Period (2026-2036) Due to the Emergence of Nove…

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...
News-Medical.Net

Adaptor proteins regulate macrophage behavior to control cancer growth

A new review was published in Volume 13 of Oncoscience on May 22, 2026, titled "Adaptor proteins regulating tumor-associated macrophage polarization during cancer progression." ...